Physician profile
Moraima Trujillo
NPI 1326130832
$121,447.23
in general payments reported to CMS, 2019-2025
17 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $23K · 2021: $22K · 2022: $14K · 2023: $9,219 · 2024: $95.24 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,136 · Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,135.75 |
| Food and Beverage | $625.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62,279.94 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $43,690.18 | 2019-2023 | Invega Sustenna |
| Alkermes, INC. | $10,585.80 | 2019-2025 | Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $4,135.12 | 2019-2020 | |
| Indivior INC. | $172.77 | 2019-2025 | Sublocade |
| Abbvie INC. | $163.08 | 2022-2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $142.67 | 2023-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $123.47 | 2024-2025 | Cobenfy |
| Braeburn INC. | $44.68 | 2024-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.59 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $24.93 | 2023 | Auvelity |
| Tempus Ai, INC | $24.22 | 2024 | |
| Phadia US INC. | $18.78 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moraima Trujillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.